BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 29172033)

  • 1. In vitro antifungal susceptibility of clinical and environmental isolates of Aspergillus fumigatus and Aspergillus flavus in Brazil.
    Bedin Denardi L; Hoch Dalla-Lana B; Pantella Kunz de Jesus F; Bittencourt Severo C; Morais Santurio J; Zanette RA; Hartz Alves S
    Braz J Infect Dis; 2018; 22(1):30-36. PubMed ID: 29172033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
    Pfaller MA; Duncanson F; Messer SA; Moet GJ; Jones RN; Castanheira M
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5155-8. PubMed ID: 21844312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
    Shivaprakash MR; Geertsen E; Chakrabarti A; Mouton JW; Meis JF
    Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
    Rudramurthy SM; Chakrabarti A; Geertsen E; Mouton JW; Meis JF
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):370-7. PubMed ID: 21937186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Diversity and
    Taghizadeh-Armaki M; Hedayati MT; Ansari S; Omran SM; Saber S; Rafati H; Zoll J; van der Lee HA; Melchers WJG; Verweij PE; Seyedmousavi S
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264849
    [No Abstract]   [Full Text] [Related]  

  • 6. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus.
    Araujo R; Pina-Vaz C; Rodrigues AG
    Int J Antimicrob Agents; 2007 Jan; 29(1):108-11. PubMed ID: 17189101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
    Pfaller MA; Carvalhaes C; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait.
    Al-Wathiqi F; Ahmad S; Khan Z
    BMC Infect Dis; 2013 Mar; 13():126. PubMed ID: 23496810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro interactions of azoles and echinocandins against clinical strains of Aspergillus flavus.
    Denardi LB; Oliveira V; de Jesus FPK; Dalla-Lana BH; Santurio JM; Zanette RA; Alves SH
    Med Mycol; 2018 Nov; 56(8):1006-1011. PubMed ID: 29294129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species.
    Wiederhold NP; Locke JB; Daruwala P; Bartizal K
    J Antimicrob Chemother; 2018 Nov; 73(11):3063-3067. PubMed ID: 30032217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.
    Arendrup MC; Perkhofer S; Howard SJ; Garcia-Effron G; Vishukumar A; Perlin D; Lass-Flörl C
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3504-11. PubMed ID: 18644959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
    Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
    Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.
    Antachopoulos C; Meletiadis J; Sein T; Roilides E; Walsh TJ
    Antimicrob Agents Chemother; 2008 Jan; 52(1):321-8. PubMed ID: 17938191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
    Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
    J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Raffetin A; Courbin V; Jullien V; Dannaoui E
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038263
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison Between Etest and Broth Microdilution Methods for Testing Itraconazole-Resistant Aspergillus fumigatus Susceptibility to Antifungal Combinations.
    Denardi LB; Keller JT; de Azevedo MI; Oliveira V; Piasentin FB; Severo CB; Santurio JM; Alves SH
    Mycopathologia; 2018 Apr; 183(2):359-370. PubMed ID: 28994001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
    Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
    Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands.
    van Ingen J; van der Lee HA; Rijs TA; Zoll J; Leenstra T; Melchers WJ; Verweij PE
    J Antimicrob Chemother; 2015 Jan; 70(1):178-81. PubMed ID: 25301884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
    Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
    J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST).
    Arendrup MC; Friberg N; Mares M; Kahlmeter G; Meletiadis J; Guinea J;
    Clin Microbiol Infect; 2020 Nov; 26(11):1464-1472. PubMed ID: 32562861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.